Allergy Therapeutics plc U.S. Regulatory Update

28 March 2011 -- Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines is pleased to announce that it met with the U.S. Food and Drug Administration (FDA) for a productive discussion. The FDA has informed the Company of its intention to lift the clinical hold in order to allow the development of MATA-MPL© products to move forward. The Company expects to receive the formal communication from the FDA in the coming weeks.

Manuel Llobet, Chief Executive of Allergy Therapeutics, said:

“We are very pleased to have received positive feedback from the FDA and look forward to providing more information when the formal communication is received.”

For further information

Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director www.allergytherapeutics.com

Nomura Code Securities +44 (0) 207 776 1200 Juliet Thompson/ Clare Terlouw

Financial Dynamics +44 (0) 207 831 3113 Ben Brewerton/ Susan Quigley

About Pollinex® Quattro

Pollinex®

Quattro is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment. It is a family of specific standardised vaccines representing a potentially extensive franchise for Allergy Therapeutics and is a novel entrant in the multibillion dollar global allergy market. It is currently available in Europe on a named patient basis.